Bicara Therapeutics
BCAX
16.00
-0.42
-2.56%
Bicara Therapeutics
US · BCAX
#3193 by market cap
Listed 2024
16.00
-0.42
-2.56%
Live - 5344 symbols - heartbeat 483s ago
· 2026-10-08 10:00
Pre-market
16.68
+1.58%
After-hours
16.42
0.00%
- Market cap
- 1.06B
- P/E (TTM)i
- -5.21
- P/Bi
- 2.26
- EPSi
- -2.52
- Div yieldi
- 0.00%
- 52W posi
- 13%
Reader sentiment
Are you bullish or bearish on BCAX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.2 percentage points.
Institutional ownership
- Held by institutions
- 115.84% -1.23pp
- Institutions
- 208 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund47.26%
VC/PE Fund41.69%
Hedge Fund15.46%
Public Company10.30%
Individual/Insider1.84%
Private Company0.79%
Government Pension Fund0.15%
Insurance Company0.14%
Top holders as of 2026-06-30
T. Rowe Price Group, Inc.
12.46% · 8.24M sh
RA Capital Management, L.P.
10.97% · 7.26M sh
Artal Group S.A.
8.47% · 5.60M sh
Biocon Limited
8.35% · 5.52M sh
Vestal Point Capital, LP
7.93% · 5.25M sh
Deep Track Capital, LP
6.20% · 4.10M sh
BlackRock
5.82% · 3.85M sh
Janus Henderson Group plc
4.79% · 3.17M sh
Red Tree Venture Capital
4.78% · 3.16M sh
TPG Capital, L.P.
4.55% · 3.01M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 10 buys · 40 sells
| Name | Role | Stake |
|---|---|---|
| RA Capital Management, L.P. | -- | 10.97% |
| Kiran Mazumdar-Shaw | Independent Director | 0.68% |
| Claire Mazumdar Clemon | Chief Executive Officer | 0.55% |
| Ryan Cohlhepp | President | 0.27% |
| Ivan Hyep | Chief Financial Officer | 0.20% |
| David Raben | Chief Medical Officer | 0.08% |
| Nils Lonberg | Independent Non-Executive Director | 0.05% |
| Kathryn Haviland | Independent Director | 0.01% |
| Michael Powell | Independent Chairperson | -- |
| Scott Robertson | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-07 | Ryan Cohlhepp | President | Derivative Exercise and Sale | -17,500 | $3.79–23.43 |
| 2026-09-07 | Ivan Hyep | Chief Financial Officer | Intent to Sell (Form 144) | -12,500 | $22.64 |
| 2026-08-09 | Ryan Cohlhepp | President | Derivative Exercise and Sale | -18,750 | $3.79–27.98 |
| 2026-08-09 | Claire Mazumdar Clemon | Chief Executive Officer | Derivative Exercise and Sale | -10,000 | $3.79–27.98 |
| 2026-08-09 | Ivan Hyep | Chief Financial Officer | Derivative Exercise and Sale | -12,500 | $3.79–27.97 |
| 2026-07-27 | Christy Oliger | Independent Director | Other Derivative Acquisition | +38,950 | $26.88 |
| 2026-07-27 | Jeremy Bender | Independent Director | Other Derivative Acquisition | +38,950 | $26.88 |
| 2026-07-09 | Claire Mazumdar Clemon | Chief Executive Officer | Derivative Exercise and Sale | -10,000 | $3.79–29.68 |
| 2026-07-08 | Ryan Cohlhepp | President | Automatic Disposition | -10,000 | $28.76–30.35 |
| 2026-07-07 | Ryan Cohlhepp | President | Derivative Exercise and Sale | -18,750 | $3.79–28.76 |
| 2026-07-07 | David Raben | Chief Medical Officer | Intent to Sell (Form 144) | -50,000 | $28.56 |
| 2026-07-07 | Ivan Hyep | Chief Financial Officer | Automatic Disposition | -15,500 | $28.60–30.31 |
| 2026-07-07 | Ivan Hyep | Chief Financial Officer | Derivative Exercise and Sale | -12,500 | $3.79–28.60 |
| 2026-06-24 | David Raben | Chief Medical Officer | Intent to Sell (Form 144) | -50,000 | $26.49 |
| 2026-06-08 | Michael Powell | Independent Chairperson | Other Derivative Acquisition | +19,475 | $20.56 |
| 2026-06-08 | Kiran Mazumdar-Shaw | Independent Director | Other Derivative Acquisition | +19,475 | $20.56 |
| 2026-06-08 | RA Capital Management, L.P. | -- | Other Derivative Acquisition | +19,475 | $20.56 |
| 2026-06-08 | Scott Robertson | Independent Director | Other Derivative Acquisition | +19,475 | $20.56 |
| 2026-06-08 | Christopher Bowden | Independent Director | Other Derivative Acquisition | +19,475 | $20.56 |
| 2026-06-08 | Kathryn Haviland | Independent Director | Other Derivative Acquisition | +19,475 | $20.56 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 10:00:10 · For reference only, not investment advice and not tailored to your situation.